Hyemin Jang

List of Publications by Year
in descending order

126 papers	1,475 citations	430874 18 h-index	454955 30 g-index
146 all docs	146 docs citations	146 times ranked	2195 citing authors

#	Article	IF	Citations
1	Assessment of Extent and Role of Tau in Subcortical Vascular Cognitive Impairment Using ^{18}F-AV1451 Positron Emission Tomography Imaging. JAMA Neurology, 2018, 75, 999.	9.0	85
2	The Cortical Neuroanatomy Related to Specific Neuropsychological Deficits in Alzheimer's Continuum. Dementia and Neurocognitive Disorders, 2019, 18, 77.	1.4	85
3	*O*-GlcNAcylation ameliorates the pathological manifestations of Alzheimer's disease by inhibiting necroptosis. Science Advances, 2021, 7, .	10.3	68
4	Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: a phase I clinical trial. Alzheimer's Research and Therapy, 2021, 13, 154.	6.2	57
5	Total MRI Small Vessel Disease Burden Correlates with Cognitive Performance, Cortical Atrophy, and Network Measures in a Memory Clinic Population. Journal of Alzheimer's Disease, 2018, 63, 1485-1497.	2.6	55
6	Head to head comparison of [18F] AV-1451 and [18F] THK5351 for tau imaging in Alzheimer's disease and frontotemporal dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 432-442.	6.4	51
7	Optical coherence tomography angiography as a potential screening tool for cerebral small vessel diseases. Alzheimer's Research and Therapy, 2020, 12, 73.	6.2	44
8	Correlations between Gray Matter and White Matter Degeneration in Pure Alzheimer's Disease, Pure Subcortical Vascular Dementia, and Mixed Dementia. Scientific Reports, 2017, 7, 9541.	3.3	39
9	A Nomogram for Predicting Amyloid PET Positivity in Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2018, 66, 681-691.	2.6	38
10	Small vessel disease more than Alzheimer's disease determines diffusion MRI alterations in memory clinic patients. Alzheimer's and Dementia, 2020, 16, 1504-1514.	0.8	35
11	Comparison of Enoxaparin and Warfarin for Secondary Prevention of Cancer-Associated Stroke. Journal of Oncology, 2015, 2015, 1-6.	1.3	33
12	Clinical significance of amyloid β positivity in patients with probable cerebral amyloid angiopathy markers. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1287-1298.	6.4	31
13	Prediction Model of Conversion to Dementia Risk in Subjects with Amnestic Mild Cognitive Impairment: A Longitudinal, Multi-Center Clinic-Based Study. Journal of Alzheimer's Disease, 2017, 60, 1579-1587.	2.6	30
14	Amyloid involvement in subcortical regions predicts cognitive decline. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2368-2376.	6.4	30
15	Prognostic value of amyloid PET scan in normal pressure hydrocephalus. Journal of Neurology, 2018, 265, 63-73.	3.6	28
16	Frontal-executive dysfunction affects dementia conversion in patients with amnestic mild cognitive impairment. Scientific Reports, 2020, 10, 772.	3.3	27
17	Appropriate reference region selection of 18F-florbetaben and 18F-flutemetamol beta-amyloid PET expressed in Centiloid. Scientific Reports, 2020, 10, 14950.	3.3	24
18	A new Centiloid method for 18F-florbetaben and 18F-flutemetamol PET without conversion to PiB. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1938-1948.	6.4	23

#	Article	IF	Citations
19	Intrathecal Injection in a Rat Model: A Potential Route to Deliver Human Wharton's Jelly-Derived Mesenchymal Stem Cells into the Brain. International Journal of Molecular Sciences, 2020, 21, 1272.	4.1	22
20	Prediction of fast decline in amyloid positive mild cognitive impairment patients using multimodal biomarkers. NeuroImage: Clinical, 2019, 24, 101941.	2.7	21
21	Non-alcoholic fatty liver disease and cerebral small vessel disease in Korean cognitively normal individuals. Scientific Reports, 2019, 9, 1814.	3.3	21
22	Predicting amyloid positivity in patients with mild cognitive impairment using a radiomics approach. Scientific Reports, 2021, 11, 6954.	3.3	20
23	Strictly Lobar Microbleeds Reflect Amyloid Angiopathy Regardless of Cerebral and Cerebellar Compartments. Stroke, 2020, 51, 3600-3607.	2.0	19
24	Amyloid Positivity in the Alzheimer/Subcortical-Vascular Spectrum. Neurology, 2021, 96, e2201-e2211.	1.1	19
25	Body Mass Index and Mortality Rate in Korean Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 46, 399-406.	2.6	18
26	Impact of smoking on neurodegeneration and cerebrovascular disease markers in cognitively normal men. European Journal of Neurology, 2016, 23, 110-119.	3.3	18
27	Concordance in detecting amyloid positivity between 18F-florbetaben and 18F-flutemetamol amyloid PET using quantitative and qualitative assessments. Scientific Reports, 2020, 10, 19576.	3.3	18
28	Hearing loss is associated with cortical thinning in cognitively normal older adults. European Journal of Neurology, 2020, 27, 1003-1009.	3.3	18
29	Trajectories of Physiological Brain Aging and Related Factors in People Aged from 20 to over-80. Journal of Alzheimer's Disease, 2018, 65, 1237-1246.	2.6	17
30	The Effects of Longitudinal White Matter Hyperintensity Change on Cognitive Decline and Cortical Thinning over Three Years. Journal of Clinical Medicine, 2020, 9, 2663.	2.4	17
31	Decreased hemoglobin levels, cerebral small-vessel disease, and cortical atrophy: among cognitively normal elderly women and men. International Psychogeriatrics, 2016, 28, 147-156.	1.0	16
32	Amyloid and cerebrovascular burden divergently influence brain functional network changes over time. Neurology, 2019, 93, e1514-e1525.	1.1	16
33	Sex-specific relationship of cardiometabolic syndrome with lower cortical thickness. Neurology, 2019, 93, e1045-e1057.	1.1	16
34	Differential effects of risk factors on the cognitive trajectory of early- and late-onset Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 113.	6.2	16
35	Distinct Brain Regions in Physiological and Pathological Brain Aging. Frontiers in Aging Neuroscience, 2019, 11, 147.	3.4	15
36	Cerebrospinal fluid from Alzheimer's disease patients as an optimal formulation for therapeutic application of mesenchymal stem cells in Alzheimer's disease. Scientific Reports, 2019, 9, 564.	3.3	15

#	Article	IF	Citations
37	Application of an amyloid and tau classification system in subcortical vascular cognitive impairment patients. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 292-303.	6.4	15
38	Prevalence of antineuronal antibodies in patients with encephalopathy of unknown etiology: Data from a nationwide registry in Korea. Journal of Neuroimmunology, 2016, 293, 34-38.	2.3	13
39	Cortical atrophy patternâ€"based subtyping predicts prognosis of amnestic MCI: an individual-level analysis. Neurobiology of Aging, 2019, 74, 38-45.	3.1	13
40	Analysis of dementia-related gene variants in APOE Îµ4 noncarrying Korean patients with early-onset Alzheimer's disease. Neurobiology of Aging, 2020, 85, 155.e5-155.e8.	3.1	13
41	Staging and quantification of florbetaben PET images using machine learning: impact of predicted regional cortical tracer uptake and amyloid stage on clinical outcomes. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1971-1983.	6.4	13
42	Head-to-Head Comparison of 18F-Florbetaben and 18F-Flutemetamol in the Cortical and Striatal Regions. Journal of Alzheimer's Disease, 2020, 76, 281-290.	2.6	13
43	Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum. Journal of Korean Medical Science, 2020, 35, e361.	2.5	13
44	Distinctive Clinical Effects of Haemorrhagic Markers in Cerebral Amyloid Angiopathy. Scientific Reports, 2017, 7, 15984.	3.3	12
45	The Impact of APOE É›4 in Alzheimerâ€™s Disease Differs According to Age. Journal of Alzheimer's Disease, 2018, 61, 1377-1385.	2.6	12
46	Clinical significance of focal ÃŸ-amyloid deposition measured by 18F-flutemetamol PET. Alzheimer's Research and Therapy, 2020, 12, 6.	6.2	12
47	Disease progression modeling of Alzheimerâ€™s disease according to education level. Scientific Reports, 2020, 10, 16808.	3.3	12
48	Performance of the plasma AÎ²42/AÎ²40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort. Alzheimer's Research and Therapy, 2021, 13, 179.	6.2	12
49	Distinct amyloid distribution patterns in amyloid positive subcortical vascular cognitive impairment. Scientific Reports, 2018, 8, 16178.	3.3	11
50	Machine Learning for the Prediction of Amyloid Positivity in Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2021, 80, 143-157.	2.6	11
51	The Impact of Amyloid-Î² or Tau on Cognitive Change in the Presence of Severe Cerebrovascular Disease. Journal of Alzheimer's Disease, 2020, 78, 573-585.	2.6	10
52	Helicobacter Pylori Infection Is Associated with Neurodegeneration in Cognitively Normal Men. Journal of Alzheimer's Disease, 2021, 82, 1591-1599.	2.6	10
53	Cortical neuroanatomical changes related to specific neuropsychological deficits in subcortical vascular cognitive impairment. NeuroImage: Clinical, 2021, 30, 102685.	2.7	9
54	Disease progression modelling from preclinical Alzheimerâ€™s disease (AD) to AD dementia. Scientific Reports, 2021, 11, 4168.	3.3	9

#	Article	IF	Citations
55	Distinctive Temporal Trajectories of Alzheimer's Disease Biomarkers According to Sex and APOE Genotype: Importance of Striatal Amyloid. Frontiers in Aging Neuroscience, 2022, 14, 829202.	3.4	9
56	Potential Applications of Artificial Intelligence in Clinical Trials for Alzheimer's Disease. Life, 2022, 12, 275.	2.4	9
57	THK5351 and flortaucipir PET with pathological correlation in a Creutzfeldt-Jakob disease patient: a case report. BMC Neurology, 2019, 19, 211.	1.8	8
58	Presynaptic dopaminergic function in early-onset Alzheimer's disease: an FP-CIT image study. Neurobiology of Aging, 2020, 86, 75-80.	3.1	8
59	Reduced forced vital capacity is associated with cerebral small vessel disease burden in cognitively normal individuals. NeuroImage: Clinical, 2020, 25, 102140.	2.7	8
60	Prediction of tau accumulation in prodromal Alzheimer's disease using an ensemble machine learning approach. Scientific Reports, 2021, 11, 5706.	3.3	8
61	Finding the optimal cutoff value for amyloid β positivity using the iterative outlier method and concordance rate. Precision and Future Medicine, 0, , .	1.6	8
62	Dopa Responsive Parkinsonism in an Early Onset Alzheimer's Disease Patient with a Presenilin 1 Mutation (A434T). Journal of Alzheimer's Disease, 2019, 71, 7-13.	2.6	7
63	The preclinical amyloid sensitive composite to determine subtle cognitive differences in preclinical Alzheimer's disease. Scientific Reports, 2020, 10, 13583.	3.3	7
64	Identifying novel genetic variants for brain amyloid deposition: a genome-wide association study in the Korean population. Alzheimer's Research and Therapy, 2021, 13, 117.	6.2	7
65	Social Event Memory Test (SEMT): A Video-based Memory Test for Predicting Amyloid Positivity for Alzheimer's Disease. Scientific Reports, 2018, 8, 10421.	3.3	6
66	Vascular Effects on Depressive Symptoms in Cognitive Impairment. Journal of Alzheimer's Disease, 2018, 65, 597-605.	2.6	6
67	Prediction of amyloid β PET positivity using machine learning in patients with suspected cerebral amyloid angiopathy markers. Scientific Reports, 2020, 10, 18806.	3.3	6
68	Diagonal Earlobe Crease is a Visible Sign for Cerebral Small Vessel Disease and Amyloid-β. Scientific Reports, 2017, 7, 13397.	3.3	5
69	Differences in neuroimaging features of early- versus late-onset nonfluent/agrammatic primary progressive aphasia. Neurobiology of Aging, 2020, 86, 92-101.	3.1	5
70	Identifying a subtype of Alzheimer's disease characterised by predominant right focal cortical atrophy. Scientific Reports, 2020, 10, 7256.	3.3	5
71	^{18}F-THK5351 PET Positivity and Longitudinal Changes in Cognitive Function in β-Amyloid-Negative Amnestic Mild Cognitive Impairment. Yonsei Medical Journal, 2022, 63, 259.	2.2	5
72	Intracerebroventricular Administration of Human Umbilical Cord Blood—Derived Mesenchymal Stem Cells Induces Transient Inflammation in a Transgenic Mouse Model and Patients with Alzheimer's Disease. Biomedicines, 2022, 10, 563.	3.2	5

#	Article	IF	Citations
73	Multimodal imaging analyses in patients with genetic and sporadic forms of small vessel disease. Scientific Reports, 2019, 9, 787.	3.3	4
74	Association between APOE Îµ2 and AÎ² burden in patients with Alzheimer- and vascular-type cognitive impairment. Neurology, 2020, 95, e2354-e2365.	1.1	4
75	Cognitive trajectories of patients with focal ÃŸ-amyloid deposition. Alzheimer's Research and Therapy, 2021, 13, 48.	6.2	4
76	Effect of education on functional network edge efficiency in Alzheimerâ€™s disease. Scientific Reports, 2021, 11, 17255.	3.3	4
77	Amyloid Positive Hydrocephalus: A Hydrocephalic Variant of Alzheimerâ€™s Disease?. Journal of Alzheimer's Disease, 2022, 85, 1467-1479.	2.6	3
78	Exploring the Potential of Mesenchymal Stem Cell-Based Therapy in Mouse Models of Vascular Cognitive Impairment. International Journal of Molecular Sciences, 2020, 21, 5524.	4.1	2
79	Heterogeneous Disease Progression in a Mouse Model of Vascular Cognitive Impairment. International Journal of Molecular Sciences, 2020, 21, 2820.	4.1	2
80	Independent effects of amyloid and vascular markers on longâ€term functional outcomes: An 8â€year longitudinal study of subcortical vascular cognitive impairment. European Journal of Neurology, 2021, , .	3.3	2
81	Development of prediction models for distinguishable cognitive trajectories in patients with amyloid positive mild cognitive impairment. Neurobiology of Aging, 2022, , .	3.1	2
82	Intraspinal Cavity Injection of Human Mesenchymal Stem Cells and Tracking their Migration into the Rat Brain. Journal of Visualized Experiments, 2021, , .	0.3	1
83	Harmonisation of PET imaging features with different amyloid ligands using machine learning-based classifier. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 321-330.	6.4	1
84	A Case of Early-Onset Alzheimerâ€™s Disease Mimicking Schizophrenia in a Patient with Presenilin 1 Mutation (S170P). Journal of Alzheimer's Disease, 2021, 83, 1025-1031.	2.6	1
85	Clinical Characteristic in Primary Progressive Aphasia in Relation to Alzheimerâ€™s Disease Biomarkers. Journal of Alzheimer's Disease, 2021, 84, 633-645.	2.6	1
86	P4â€196: Clinical Impacts of Cortical Superficial Siderosis in Patients With Clinically Diagnosed Cerebral Amyloid Angiopathy. Alzheimer's and Dementia, 2016, 12, P1099.	0.8	0
87	[P1â€224]: [18]Fâ€AV1451 PET IMAGING IN SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P329.	0.8	0
88	[P2â€406]: IN VIVO BRAAK STAGING OF AMNESTIC MCI USING [18]Fâ€THK5351 PET IMAGING. Alzheimer's and Dementia, 2017, 13, P786.	0.8	0
89	[P2â€407]: PREVALENCE OF AMYLOIDâ€PET POSITIVITY ACCORDING TO AGE AND *APOE* GENOTYPE IN PATIENTS WITH SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P787.	0.8	0
90	[P2â€424]: PROTECTIVE EFFECTS OF EDUCATION ON THKâ€5351 UPTAKES IN MILD COGNITIVE IMPAIRMENT WITH SUSPECTED NONâ€ALZHEIMER PATHOLOGY. Alzheimer's and Dementia, 2017, 13, P798.	0.8	0

#	Article	IF	Citations
91	[P3–194]: DIAGONAL EARLOBE CREASE, CEREBRAL SMALL VESSEL DISEASE, AND BETA–AMYLOIDOSIS IN COGNITIVELY IMPAIRED PATIENTS. Alzheimer's and Dementia, 2017, 13, P1009.	0.8	0
92	[P3–258]: TRAJECTORIES OF COGNITIVE DECLINE IN SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1042.	0.8	0
93	[P3–337]: THK5351 UPTAKES IN EARLY AND LATE STAGES OF AMNESTIC MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1082.	0.8	0
94	[P3–413]: CLINICAL EFFECT OF SMALL–VESSEL DISEASE AND WHITE MATTER NETWORK ON DEPRESSION IN PATIENTS WITH COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1124.	0.8	0
95	[P4–169]: COGNITIVE TRAJECTORIES IN PATIENTS WITH NON–AMNESTIC MILD COGNITIVE IMPAIRMENT: A LONGITUDINAL STUDY. Alzheimer's and Dementia, 2017, 13, P1326.	0.8	0
96	[P1–423]: THE DEVELOPMENT OF AN ALZHEIMER's DISEASE RISK SCORE BASED ON THE CORTICAL THICKNESS ANALYSES. Alzheimer's and Dementia, 2017, 13, P440.	0.8	0
97	[P1–428]: NON–ALCOHOLIC FATTY LIVER DISEASE AND CEREBRAL SMALL–VESSEL DISEASE IN COGNITIVELY NORMAL INDIVIDUALS. Alzheimer's and Dementia, 2017, 13, P443.	0.8	0
98	[P1–454]: POSITIVE ASSOCIATION BETWEEN EDUCATION AND THK–5351 UPTAKES IN PATIENTS WITH ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P460.	0.8	0
99	[P2–318]: RISK SCORE FOR THE PREDICTION OF DEMENTIA RISK IN SUBJECTS WITH AMNESTIC MILD COGNITIVE IMPAIRMENT: A LONGITUDINAL, MULTI–CENTER CLINIC–BASED STUDY. Alzheimer's and Dementia, 2017, 13, P739.	0.8	0
100	[O4–04–03]: SYNERGISTIC EFFECT OF TAU, AMYLOID, AND VASCULAR BURDEN ON COGNITIVE DECLINE IN PATIENTS WITH SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENTS. Alzheimer's and Dementia, 2017, 13, P1235.	0.8	0
101	P1–382: COMPARISON OF AD PATHOLOGIES IN HYPERTENSIVE SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT AND CEREBRAL AMYLOID ANGIOPATHY. Alzheimer's and Dementia, 2018, 14, P445.	0.8	0
102	P1–386: AMYLOID AND CEREBROVASCULAR BURDEN INFLUENCES ON LONGITUDINAL BRAIN FUNCTIONAL CONNECTIVITY CHANGES IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2018, 14, P448.	0.8	0
103	O1–14–01: PULMONARY FUNCTION AND CEREBRAL SMALL VESSEL DISEASE AND CORTICAL THINNING IN COGNITIVELY NORMAL INDIVIDUALS. Alzheimer's and Dementia, 2018, 14, P256.	0.8	0
104	P2–319: DISEASE COURSE MODELING OF ALZHEIMER'S DISEASE DEPENDING ON AMYLOID DEPOSITION: AN ACCELERATED LONGITUDINAL DESIGN. Alzheimer's and Dementia, 2018, 14, P804.	0.8	0
105	IC–P–121: EFFECTS OF CARDIOMETABOLIC RISK FACTORS ON BRAIN AGING IN THE ELDERLY. Alzheimer's and Dementia, 2018, 14, P102.	0.8	0
106	P1–407: ALZHEIMER'S DISEASE WITH RIGHT FOCAL CORTICAL ATROPHY. Alzheimer's and Dementia, 2018, 14, P459.	0.8	0
107	IC–P–078: CLINICAL SIGNIFICANCE OF A/T/N SYSTEM IN SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT PATIENTS. Alzheimer's and Dementia, 2018, 14, P69.	0.8	0
108	P3–393: A NOMOGRAM FOR PREDICTING AMYLOID PET POSITIVITY IN AMNESTIC MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2018, 14, P1248.	0.8	0

#	Article	IF	Citations
109	O1â€14â€03: NATURAL HISTORY OF SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT: AN 8.5â€YEAR LONGITUDINAL STUDY. Alzheimer's and Dementia, 2018, 14, P258.	0.8	0
110	P1â€483: COGNITIVE RESERVE AND EFFICIENCY NETWORK: IN NORMAL COGNITION, AMNESTIC MCI AND ALZHEIMER'S DEMENTIA. Alzheimer's and Dementia, 2018, 14, P511.	0.8	0
111	P3â€346: CLINICAL SIGNIFICANCE OF AMYLOID BETA POSITIVITY IN PATIENTS WITH CEREBRAL AMYLOID ANGIOPATHY MARKERS. Alzheimer's and Dementia, 2018, 14, P1216.	0.8	0
112	ICâ€Pâ€050: AMYLOID DEPOSITION IN THE SUBCORTICAL REGION PREDICTS COGNITIVE DECLINE. Alzheimer's and Dementia, 2018, 14, P49.	0.8	0
113	P3â€425: ALZHEIMER'S DEMENTIA CONVERSION IN AMNESTIC MCI ACCORDING TO NEUROPSYCHOLOGICAL PROFILE. Alzheimer's and Dementia, 2018, 14, P1272.	0.8	0
114	Clinical Effects of Frontal Behavioral Impairment: Cortical Thickness and Cognitive Decline in Individuals with Subjective Cognitive Decline and Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2019, 69, 213-225.	2.6	0
115	The effect of smartphone appâ€based cognitive training on cognition in communityâ€dwelling elderly: A randomized controlled trial. Alzheimer's and Dementia, 2020, 16, e039268.	0.8	0
116	Optical coherence tomography angiography in cognitively impaired patients: Vascular and neurodegenerative perspectives. Alzheimer's and Dementia, 2020, 16, e041738.	0.8	0
117	H. pylori infection is associated with cortical thinning in cognitively normal individuals. Alzheimer's and Dementia, 2020, 16, e044295.	0.8	0
118	Thymoma-Associated Paraneoplastic Myositis, Presenting with Rapidly Progressive Muscle		